Interview with hugely successful investor Jim Mellon at the Undoing Aging conference in Berlin 2019!
We cover reasons why it’s a good time to invest in Anti-Aging and rejuvenation biotechnology today, the ethical reasons why we should, and effective advocacy: i.e. what one would say to a billionaire to convince them that investing in longevity medicine is a good thing to do now.
Jim raised over $150 Million for his venture Juvenescence recently!
Bio: Jim Mellon is an investor with an interest in several industries. After studying PPE at Oxford, Jim worked in Asia and in the US for two fund management companies, GT Management and Thornton & Co, before establishing his own business in 1991. This business is now known by two names – Charlemagne Capital, recently acquired, and Regent Pacific Group, listed in Hong Kong. Jim’s private investment company, The Burnbrae Group, is a substantial landlord in Germany and the Isle of Man, and owns the group Sleepwell Hotels. Jim is chairman and major shareholder of Manx Financial Group, Port Erin Biopharma Invesments and SalvaRx Group. He is also a director of Condor Gold, Fast Forward Innovations, Portage Biotech and West African Minerals Corporation, all publicly listed companies. Amongst his many successes, Jim is well known for notching up one of the AIM market’s biggest successes with the sale of Uramin to Areva, the French nuclear giant.
Book ‘Juvenescence: Investing in the age of longevity’ –
Many thanks for watching!
Consider supporting SciFuture by:
a) Subscribing to the SciFuture YouTube channel:
– Bitcoin: 1BxusYmpynJsH4i8681aBuw9ZTxbKoUi22
– Etherium: 0xd46a6e88c4fe179d04464caf42626d0c9cab1c6b
c) Sharing the media SciFuture creates:
– Science, Technology & the Future